Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）

Inclusion Criteria: * 1.Patients with histologically confirmed advanced renal cell carcinoma including clear cell component and not available for surgery * 2.Without drug treatment for RCC or chemotherapy/cytokine therapy failure or resistant patients) * 3.With measurable disease (using RECIST1.1) * 4.18-75years,ECOG PS:0-1,Life expectancy of more than 3 months * 5.Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks * 6.main organs function is normal * 7.Signed and dated informed consent Exclusion Criteria: * 1.Previously received targeted therapy of the metastatic renal cell carcinoma (such as sunitinib, Sorafenib) * 2.patients has many influence factors toward oral medications * 3.Known brain metastases * 4.patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)\>10mmol/L);urine protein≥++,etc. * 5.patients failed to heal wounds or fractures for Long-term * 6.patients occurred venous thromboembolic events within 6 months * 7.patients has HIV-positive or organ transplantation